secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2026-08-10T11:00:41+00:00
Accession:  0001213900-26-086933
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Q2 net loss $41.2M; EVERLAST-A 63.5% PASI 100; cash $1.1B
---------------------------------------------------------------

- Q2 2026 net loss $41.2M vs $24.6M in Q2 2025; R&D spend $43.3M; cash $1.1B funds through BLA filing.
- EVERLAST-A Phase 2a: 40/63 (63.5%) achieved PASI 100 at Week 16; PASI 90 83%; IGA 0/1 84%.
- EVERLAST-B fully enrolled (187 subjects); Week 16 data expected Q4 2026; Phase 3 for ORKA-001 in 1H 2027.
- ORCA-SPLASH Phase 2 in HS initiated (~160 patients); ORKA-004 TL1A antibody enters clinic Q4 2026.
- May 2026: IL-23 license with Paragon amended to include all therapeutic areas incl. IBD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/0001213900-26-086933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/ea0301312-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-086933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer